LonzaRegister for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Lonza (LONN.SW) reported revenue of $3.81B in Q2 2026.
H2 2016-H1 2026
H2 2016-H1 2026
LonzaCDMO for mRNA drug substance, lipid-nanoparticle formulation, and sterile fill-finish. Shared capacity calendar with GLP-1 peptide fill-finish.
Lonza (LONN.SW) is a Diagnostics & Research company. CDMO for mRNA drug substance, lipid-nanoparticle formulation, and sterile fill-finish. Shared capacity calendar with GLP-1 peptide fill-finish. It was founded in 1897, is headquartered in Basel, Switzerland and employs about 18,000 people.
Track Lonza's quarterly and annual revenue, gross and net margins, and EPS in the interactive charts on this page. Data last updated August 19, 2026.
Sterling groups Lonza in the Vaccines sector, alongside GSK (GSK), Pfizer (PFE), Merck & Co. (MRK), Sanofi (SNY), Moderna (MRNA) and BioNTech (BNTX).
If you are researching Lonza, also look at GSK (GSK), Pfizer (PFE) and Merck & Co. (MRK). You can compare all of them side by side or browse the full Vaccines sector on Sterling.